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Aims Cardiac ischaemia does not elicit an efficient angiogenic response. Indeed, lack of surgical revascularization upon
myocardial infarction results in cardiomyocyte death, scarring, and loss of contractile function. Clinical trials aimed
at inducing therapeutic revascularization through the delivery of pro-angiogenic molecules after cardiac ischaemia
have invariably failed, suggesting that endothelial cells in the heart cannot mount an efficient angiogenic response.
To understand why the heart is a poorly angiogenic environment, here we compare the angiogenic response of the
cardiac and skeletal muscle using a lineage tracing approach to genetically label sprouting endothelial cells.
....................................................................................................................................................................................................
Methods
and results
We observed that overexpression of the vascular endothelial growth factor in the skeletal muscle potently stimu-
lated angiogenesis, resulting in the formation of a massive number of new capillaries and arterioles. In contrast, re-
sponse to the same dose of the same factor in the heart was blunted and consisted in a modest increase in the
number of new arterioles. By using Apelin-CreER mice to genetically label sprouting endothelial cells we observed
that different pro-angiogenic stimuli activated Apelin expression in both muscle types to a similar extent, however,
only in the skeletal muscle, these cells were able to sprout, form elongated vascular tubes activating Notch signal-
ling, and became incorporated into arteries. In the heart, Apelin-positive cells transiently persisted and failed to give
rise to new vessels. When we implanted cancer cells in different organs, the abortive angiogenic response in the
heart resulted in a reduced expansion of the tumour mass.
....................................................................................................................................................................................................
Conclusion Our genetic lineage tracing indicates that cardiac endothelial cells activate Apelin expression in response to pro-
angiogenic stimuli but, different from those of the skeletal muscle, fail to proliferate and form mature and structured
vessels. The poor angiogenic potential of the heart is associated with reduced tumour angiogenesis and growth of
cancer cells.
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1. Introduction
It is common experience that heart ischaemia does not elicit an efficient
angiogenic response, able to restore an appropriate supply of oxygen
and nutrients to the hypoxic region. If not promptly revascularized, the
infarcted myocardium inevitably heals by scarring, with detrimental con-
sequences on heart function.1 Various angiogenic factors are up-regu-
lated early after ischaemia, indicating a spontaneous attempt of the heart
to induce the formation of new blood vessels and revascularize the
ischaemic region.2,3 Yet, this process does not result in an efficient angio-
genic response, consistent with the failure of clinical trials aimed at induc-
ing therapeutic angiogenesis in the heart.4,5 In addition, recent
experimental evidence showed that collateral vessels after myocardial
infarction are formed by arteriogenesis (i.e. the appearance of visible ar-
teries from pre-existing small arterioles by rapid lumen opening and vas-
cular wall thickening) and not by angiogenesis.6
Different from the heart, tumours have a remarkable capacity to form
new blood vessels in response to hypoxia. During tumour growth, the
central core becomes progressively hypoxic, inducing the expression of
multiple angiogenic factors, among which the most potent is the vascular
endothelial growth factor (VEGF). The VEGF gene encodes for a tran-
script that is alternatively spliced to produce multiple isoforms, each one
characterized by different angiogenic potential.4 The most potent iso-
form is the one composed by 165 amino acids (VEGF165),7 herein re-
ferred to as VEGF. Tumour-derived VEGF potently promotes the
formation of new capillaries, thus supporting the further growth of can-
cer cells.8 The reasons why a hypoxic tumour efficiently induces an an-
giogenic response, leading to new blood vessel formation, whereas a
hypoxic heart fails to do the same are currently not understood.
Our laboratory has a long-lasting interest in the use of vectors derived
from the adeno-associated virus (AAV) for the induction of therapeutic
angiogenesis through the delivery of VEGF. This strategy was very effec-
tive in promoting the massive formation of new blood vessels after either
hind limb ischaemia, or other ischaemic diseases, in which the vector was
delivered to the skeletal muscle.9–12 However, when we applied the
same approach to cardiac ischaemia, we have never observed any re-
markable angiogenic response and eventually discovered a direct, pro-
tective effect of VEGF on cardiomyocytes, independent from
angiogenesis.13 In particular, the delivery of AAV-VEGF after myocardial
infarction did not result in a significant endothelial cell proliferation and
generation of new capillaries, however, we observed an increased num-
ber of arteries,13,14 again consistent with ongoing arteriogenesis.6
To experimentally assess whether the skeletal and cardiac muscle dif-
ferentially respond to angiogenic stimuli, we took advantage of a genetic
lineage tracing approach, in which the Tamoxifen-inducible form of the
Cre recombinase (CreER) is expressed under the control of the Apelin
(Apln) promoter.15 Apelin is a highly conserved secreted peptide, acting
as the endogenous ligand for the human G protein-coupled receptor
APJ.16 Endothelial cells express abundant levels of Apelin during embry-
onic development, when angiogenesis is active in almost all organs, and
markedly down-regulates its expression in adulthood, when they be-
come quiescent.15,17 However, in response to hypoxia, under tissue is-
chaemia or in the context of a tumour, Apelin expression is typically
reactivated, particularly by tip cells, which induce stalk cell proliferation
through Dll4/Notch1 signalling,18,19 during sprouting angiogenesis.17,20
Thus, the Apln-CreER mouse is a powerful tool to genetically label
sprouting endothelial cells and their progeny.6,15 Here, we take advan-
tage of this mouse strain to analyse the response of cardiac and skeletal
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muscle endothelial cells to pro-angiogenic stimuli and follow their fate in
the two organs in vivo.
2. Methods
Extended materials and methods are provided as Supplementary
material online.
2.1 AAV vector production and
administration
All rAAV vectors were produced by the AAV Vector Unit at ICGEB
Trieste (https://www.icgeb.org/facilities/avu-core-facility/).7 AAV9
(herein referred to as AAV) vectors were injected into either the tibialis
anterior muscle or the left ventricular wall of the adult heart using a 30G
syringe.7,21
2.2 DNA and RNA extraction and
quantification
Total DNA was isolated using the DNeasy Blood and Tissue Kit to de-
tect and quantify vector DNA by real-time PCR.21 Total RNA was iso-
lated using TRIzol Reagent. Reverse transcription was performed using
First Strand cDNA Synthesis Kit with random primers. The expression
of VEGF and Gapdh was detected using specific primers and TaqManVR
probes, while the expression of Notch1, Hes1, and Hey was detected us-
ing SYBR Green.
2.3 Protein extraction and VEGF
quantification
Proteins were extracted from the skeletal and cardiac muscle using RIPA
buffer supplemented with protease inhibitors. The amount of mouse
and human VEGF were quantified using Mouse VEGF Quantikine ELISA
(R&D systems) and VEGF human ELISA (Abcam) kits. Data were nor-
malized on protein content.
2.4 Mice
All animal experiments were conducted in accordance with guidelines
from the Directive 2010/63/EU of the European Parliament on animal
experimentation in compliance with European guidelines and
International Laws and Policies (EC Council Directive 86/609, OJL 34, 12
December 1987). CD1, Balb/c, and C57BL/6 mice were purchased from
Harlan Laboratories. Adult AplnCreER6 mice were crossed with
Rosa26-mT/mG mice22 to obtain AplnCreER; Rosa26-mT/mG animals.
To activate Cre-mediated recombination, 4-hydroxytamoxifen
was dissolved in corn oil and injected intraperitoneally. To label prolifer-
ating cells, 5-ethynyl-20-deoxyuridine (EdU) was administered
intraperitoneally.
B16-F10 melanoma and LG1233 lung adenocarcinoma cells were
injected into C57BL/6 mice either into the tibialis anterior skeletal mus-
cle or the left ventricular wall of the heart. Breast cancer 4T1cells were
injected into Balb/c mice. B16-F10 and 4T1 cells were also injected sub-
cutaneously into the right flank. Tumour volume was measured using the
formula: V = p/6*(dmax
2 * dmin/2).
23
Mice were anaesthetized with 1% isoflurane for intramuscular injec-
tions and with ketamine–xylazine (100–40 mg/kg) for intracardiac injec-
tions. At the end of the experiment, mice were anaesthetized with 5%
isoflurane and euthanized by cervical dislocation.
2.5 Primary endothelial cell cultures and
spheroids
Endothelial cells were selected by magnetic separation and plated in pri-
mary 96-well plates coated with fibronectin/gelatin in EGM-2 medium.
For Apelin expression assay, cells were cultured in the presence of both
4-hydroxytamoxifen and recombinant human VEGF. For endothelial
spheroid formation, cells were seeded into agarose-coated round bot-
tom plates. Spheroids were transferred on top of a collagen layer and
cultured in EGM-2 medium supplemented with 4-hydroxytamoxifen to
allow endothelial cell sprouting and EGFP expression.
2.6 Western blot
Protein lysates were run in 10% polyacrylamide gels and transferred to
nitrocellulose membranes probed with the following antibodies:
VEGFR2 (Santa Cruz Biotechnology, sc-504), Akt1 (Cell Signaling
Technology, 2938), phospho-Akt (Cell Signaling Technology, 4056),
Erk1/2 (Cell Signaling Technology, 9102), phospho-Erk1/2 (Santa Cruz
Biotechnology, sc-136521), tubulin (Merck, T5168), and b-actin (Merck,
A3854).
2.7 Immunofluorescence, image acquisition
and analysis
Hearts and skeletal muscles were fixed in paraformaldehyde (PFA) and
equilibrated in sucrose before embedding in OCT and cryosectioning.
Sections were transferred on microslides, permeabilized in Triton X-
100, blocked in BSA and incubated with primary antibodies. Cells were
fixed in PFA, permeabilized, blocked, and incubated with primary anti-
bodies. Alexa Fluor-conjugated secondary antibodies were used to de-
tect primary antibodies, while nuclei were counterstained with Hoechst.
EdU incorporation was visualized using the EdU Click-iT assay. Images
were acquired using a Nikon fluorescent microscope, a Zeiss LSM 880
confocal microscope and analysed using ImageJ2 software.24 Three-
dimensional rendering of 100lm thick sections were obtained using
Surface module of Imaris (Bitplane).
2.8 Flow cytometry and cell sorting
Samples were stained using antibodies specific for CD31, Dll4, VEGFR1,
and CD45. Cells were acquired using a FACSCelesta and sorted using a
FACS Aria II (BD).
2.9 Statistical analysis
Statistical analysis was performed using Excel and GraphPad Prism 7.0
on data expressed as mean ± standard error. Unpaired Student’s t-test
and one-way analysis of variance (ANOVA) with Student–Newman–
Keuls correction were used to determine statistical significance for the
normally distributed datasets, whereas non-normally distributed datasets
were analysed by ANOVA on ranks and Mann–Whitney U test. P-value
<0.05 was considered significant.
3. Results
3.1 The cardiac muscle is less responsive to
VEGF than the skeletal muscle
To analyse the angiogenic response elicited by VEGF in either the skele-
tal or cardiac muscle, we injected the same dose of AAV-VEGF into the
tibialis anterior and the left ventricular wall of 8 weeks old CD1 mice, us-
ing an empty AAV vector as a control (AAV-control). Animals were
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injected with the thymidine analogue EdU every other day starting from
Day 14 after vector administration, to specifically assess the proliferative
response of endothelial cells to VEGF. All animals were eventually sacri-
ficed at Day 30 for molecular and histological evaluation, as schematically
represented in Figure 1A. As expected, the number of AAV viral genomes
was comparable in the two tissues (Figure 1B) and this resulted also in
comparable levels of both human VEGF mRNA and protein in both tis-
sues (Figure 1C and D).
Consistent with previous data,7,9 we found that VEGF-induced mas-
sive formation of new a-SMAþ arterioles (with a diameter in the 20–
200lm range) in the skeletal muscle. While the AAV-MCS-injected
muscle contained 4 ± 0.25 arterial vessels per field, this number raised up
to 13.7± 1.1 upon the injection of AAV-VEGF. In contrast, the increase
in the number of arterial vessels was modest in the heart (4.8 ± 0.2 and
6.3 ± 0.8 arteries per field in response to AAV-control and AAV-VEGF,
respectively). Similar results were obtained by quantifying the number of
pixels corresponding to a-SMAþ signal, as shown in Figure 1E and G. The
difference in the number of capillaries formed in response to VEGF in
the two organs was even more evident. While the number of either
CD31þ (Figure 1E and H) or ERGþ endothelial cells (Figure 1F and I)
markedly increased upon AAV-VEGF injection in the skeletal muscle, no
induction of angiogenesis was observed in the adult heart (Figure 1E, F, H,
and I). In contrast, VEGF-induced angiogenesis was robust in neonatal
hearts (Supplementary material online, Figure S1A–G).
By assessing EdU incorporation in endothelial cells, we observed a
massive proliferative response of CD31þ endothelial cells in the skeletal
muscle and in the neonatal heart, but only a minimal effect in the adult
heart (Figure 1J and K and Supplementary material online, Figure S1H and
I).
Taken together, these results indicate that the response of endothelial
cells to VEGF is blunted after birth in the heart, while it remains robust in
the adult skeletal muscle.
3.2 VEGF induces sprouting angiogenesis in
the skeletal but not in the cardiac muscle
To further characterize the angiogenic capacity of adult skeletal muscle
and heart, we took advantage of a transgenic mouse enabling the genetic
tracing of Apelin-expressing cells and their progeny (Apln-CreER;
R26mT/mG). In this mouse, membrane-localized tdTomato is produced
by all cells, while it switches to membrane-EGFP upon tamoxifen-
inducible Cre recombination, occurring only in Apelinþ cells. This mouse
has been previously used to genetically label sprouting endothelial
cells.15
We injected either AAV-VEGF or AAV-control in the skeletal muscle
and heart of these mice, followed by tamoxifen administration at Days 1
and 7 (Figure 2A). Also in this mouse strain, VEGF overexpression resulted
in an increased number of endothelial cells in the skeletal muscle but not
in the heart, as detected by the two endothelial markers CD31 and ERG.
In both muscle types, the fraction of Apelinþ endothelial cells was signifi-
cantly increased in response to VEGF, indicative of proper response to
the growth factor at the individual cell level (Figure 2B, C, and E). These
Apelinþ cells were incorporated in the VEGF-induced arterioles in the
skeletal muscle, but not in the heart (Figure 2D and F). Apelinþ cells were
negative for the pan-leukocytic marker CD45 (Supplementary material
online, Figure S2), consistent with their endothelial identity.
To assess whether cardiac endothelial cells were able to respond to a
higher dose of VEGF, we injected a 100-fold concentrated viral prepara-
tion (Supplementary Figure S3A) in either the heart or the skeletal muscle
of Apln-CreER; R26mT/mG mice. We did not detect any increase in the
number of arteries containing EGFPþ endothelial cells in any of the two
organs compared with the initial concentration of the virus (compare
Figure 2D with Supplementary material online, Figure S3B and D). On the
other hand, a 100-fold diluted preparation did not elicit any angiogenic
response in any muscle type (Supplementary material online, Figure S3C
and D).
Thus, VEGF is sensed by endothelial cells in both skeletal and cardiac
muscle. In the latter tissue, however, it fails to induce further steps of an-
giogenesis and Apelinþ cells do not contribute to the formation of
arterioles.
3.3 Tumour cell-induced angiogenesis is im-
paired in the heart
We wondered whether the response to other angiogenic stimuli might
also be impaired in the adult heart. In particular, we investigated cancer-
associated angiogenesis, knowing that the heart is one of the exceptional
organs in the body in which both primary and secondary tumours are ex-
tremely rare.25 By taking advantage of the documented capacity of Apln-
CreER; R26mT/mG mice to label sprouting endothelial cells within
tumours,15 we implanted lung cancer LG cells in either the tibialis ante-
rior or the left ventricle of these mice, followed by tamoxifen administra-
tion at Days 1 and 4. Animals were sacrificed at Day 3, 6, and 9 after
tumour cell injection for histological evaluation of angiogenesis
(Figure 3A). Within the tumours implanted in the skeletal muscle, the
number of EGFPþCD31þ endothelial cells progressively increased over
time, resulting markedly higher at Day 9 compared with the surrounding,
healthy tissue. In contrast, in the heart, endothelial cells switched on
Apelin expression early after cancer cell implantation, but the number of
these cells within the tumour area progressively decreased, becoming
similar to that found in the surrounding, non-infiltrated myocardium at
Day 9 (quantification in Figure 3B and representative images at Day 9
inFigure 3D; images of the entire time course are in Supplementary mate-
rial online, Figure S4A).
Next, we wondered whether the progressive decrease in the number
of Apelinþ endothelial cells in tumour-implanted hearts could be due to
their death. By staining tissue sections for the apoptosis marker cleaved
Caspase-3, we observed the presence of numerous apoptotic EGFPþ
cells, particularly evident at Day 6 after cancer cell implantation in the
heart (representative images and quantification in Supplementary mate-
rial online, Figure S5). No apoptotic cells were detected in the skeletal
muscle.
In the same samples, the number of EGFPþ arterioles in the skeletal
muscle significantly increased over time in the tumour region compared
with the surrounding, non-infiltrated tissue (quantification in Figure 3C
and representative images at Day 9 in Figure 3E; images of the entire time
course are in Supplementary material online, Figure S4B). In contrast,
very few EGFPþ arteries were detected in the heart, either within
tumours or in the surrounding area (Figure 3C and E).
These results reiterate that, similar to what we observed in response
to AAV-VEGF, cancer cells induce Apelin expression in endothelial cells
of both skeletal muscle and heart, but in the latter organ Apelinþ cells
die and do not become incorporated into the cancer-associated vessels.
To investigate whether the different angiogenic capacity of skeletal
muscle and heart might impact on tumour cell survival and proliferation,
we monitored LG tumour volume over time. We found that cancer cells
grew at a slower rate in the cardiac than in the skeletal muscle at all ana-
lysed time points (Figure 4A). This marked difference was attributable to
4 T. Kocijan et al.
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Figure 1 VEGF induces a potent angiogenic response in the skeletal but not in the cardiac muscle. (A) Schematic of the AAV and EdU injection. (B) Real-
time PCR quantification of the number of AAV viral genomes (vg) in the skeletal muscle (SM) and cardiac muscle (CM) normalized on tissue weight. (C)
Real-time PCR quantification of human VEGF mRNA normalized on mouse GAPDH. (D) Quantification of mouse and human VEGF by ELISA assay normal-
ized on tissue weight. (E) Representative immunofluorescence staining of skeletal and cardiac muscle, injected with either AAV-control (left) or AAV-VEGF
(right), using anti-a-SMA and anti-CD31 antibodies. (F) Representative immunofluorescence staining of skeletal and cardiac muscle, injected with either
AAV-control (left) or AAV-VEGF (right), using anti-ERG antibodies. (G) Quantification of the area covered by a-SMAþ cells. (H) Quantification of the area
covered by CD31þ cells. (I) Quantification of the percentage of ERGþ nuclei. (J) Quantification of the percentage of EdUþ CD31þ cells. (K) Representative
immunofluorescence staining of skeletal and cardiac muscle, injected with either AAV-control (left) or AAV-VEGF (right) showing EdUþ nuclei and CD31þ
endothelial cells. The inset shows a higher magnification to visualize EdUþCD31þ endothelial cells (indicated by arrows). In B–D, G–J data are shown as
mean ± S.E.M. Statistical significance was determined using a two-way ANOVA followed by Tukey’s multiple comparison test, *P< 0.05, ***P< 0.001, n= 3–
5 per group. Scale bar in E, F, and K 100lm.
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..both reduced proliferation and increased apoptotic death of cancer cells
in the heart, as shown by staining for the proliferation marker Ki67 and
the apoptosis marker cleaved Caspase-3 (quantification in Figure 4B and
C and representative images in Figure 4D and E).
We also wanted to confirm these findings using two additional cancer
cell lines. We injected the same number of 4T1 breast cancer cells and
B16-F10 melanoma cells into either the skeletal or cardiac muscle of syn-
geneic Balb/c and C57BL/6 mice, respectively. At 15 days, tumours were
clearly detectable by gross examination of the injected organs.
Representative pictures of control skeletal and cardiac muscles and the
same organs injected with LG, B16-F10, and 4T1 cells are shown in
Figure 4F–I. For all the tested cell lines, tumours formed in the skeletal
muscle were invariably larger than those formed in the heart (Figure 4J–
L) and similar to those implanted subcutaneously (Supplementary mate-
rial online, Figure S6).
Collectively, these results are consistent with the conclusion that
sprouting endothelial cells efficiently contribute to cancer-associated an-
giogenesis in the skeletal muscle, but fail to do so in the heart.
3.4 Cardiac endothelial cells sense the
VEGF stimulus but fail to sprout ex vivo
Since we detected a similar expression of Apelin in both organs early af-
ter the angiogenic stimulus, we aimed at assessing the angiogenic poten-
tial of primary endothelial cells isolated from both tissues. First, we
isolated endothelial cells from Apln-CreER; R26mT/mG mice and ex-
posed them to both tamoxifen and VEGF for 48 h. Consistent with the
in vivo results, we observed that both cell types activated Apelin expres-
sion in response to VEGF (Figure 5A and B). Next, we assessed their pro-
liferation and found that the number of Ki67þ cells isolated from the
skeletal muscle significantly increased upon VEGF administration, while
that of cardiac cells did not (Figure 5C and D). In both cases, proliferating
endothelial cells were largely negative for Apelin (the percentage of
Ki67þ EGFPþ cells was invariably lower than 0.05, as shown by represen-
tative images in Supplementary material online, Figure S7A). While we did
not detect any major difference in the expression of the major pro-
angiogenic receptor VEGFR2, downstream signalling pathways resulted
Figure 2 Sprouting Apelinþ endothelial cells differentially contribute to the formation of arterial vessels in response to VEGF in the skeletal and cardiac
muscle. (A) Schematic of AAV and tamoxifen (Tam) injection in Apln-CreER; R26mT/mG mice. (B) Quantification of the number of EGFPþ CD31þ endo-
thelial cells (% of CD31þ cells). (C) Quantification of the number of EGFPþ ERGþ endothelial cells (% of ERGþ cells). (D) Quantification of the number of ar-
teries containing EGFPþ endothelial cells (% of total arteries). (E) Representative immunofluorescence staining of skeletal and cardiac muscle of Apln-
CreER; R26mT/mG mice injected with either AAV-control (left) or AAV-VEGF (right), labelled with anti-CD31 antibodies. Boxed regions are shown as split
channels in the panels on the right. (F) Representative immunofluorescence staining of skeletal and cardiac muscle of Apln-CreER; R26mT/mG mice injected
with either AAV-control (left) or AAV-VEGF (right), labelled with anti-a-SMA antibodies. In (B–D) data are shown as mean ± S.E.M. Statistical significance
was determined using a two-way ANOVA followed by Tukey’s multiple comparison test, ***P< 0.001, n>_ 7 per group. Scale bar in E, F, 100lm.
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Figure 3 Sprouting Apelinþ endothelial cells differentially contribute to tumour angiogenesis in the skeletal and cardiac muscle. (A) Schematic of LG cell
and tamoxifen (Tam) injection in Apln-CreER; R26mT/mG mice. (B) Quantification of the number of EGFPþ endothelial cells (% of CD31þ cells) at the indi-
cated time points in either the tumour region or the surrounding, healthy tissue. (C) Quantification of the number of arteries containing EGFPþ endothelial
cells (% of total arteries) at the indicated time points in either the tumour region or the surrounding, healthy tissue. (D) Representative immunofluorescence
staining of skeletal and cardiac muscle of Apln-CreER; R26mT/mG mice injected with LG cells, labelled with anti-CD31 antibodies 9 days after cancer cell in-
jection. Panels on the left show regions highly infiltrated by cancer cells, whereas panels on the right show the surrounding, healthy tissue. Boxed regions are
magnified in the lower panels to show split channels. (E) Representative immunofluorescence staining of skeletal and cardiac muscle of Apln-CreER;
R26mT/mG mice injected with LG cells, labelled with anti-a-SMA antibodies 9 days after cancer cell injection. Panels on the left show regions highly infil-
trated by cancer cells, whereas panels on the right show the surrounding, healthy tissue. In (B, C) data are shown as mean ± S.E.M. Statistical significance was
determined using a two-way ANOVA followed by Tukey’s multiple comparison test, *P< 0.05, **P< 0.01, ***P< 0.001, n= 3 per group. Scale bar in D, E
200lm.
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Figure 4 Tumours grow less in the heart than in the skeletal muscle. (A) Quantification of tumour size at different time points after LG cell implantation
into either the skeletal or the cardiac muscle. (B) Quantification of Ki67þ nuclei (% of total nuclei) in sections of either skeletal or cardiac muscle at 10 days
after LG cell implantation. (C) Quantification of cleaved Caspase-3þ cells in sections of either skeletal or cardiac muscle at 10 days after LG cell implantation.
(D) Representative immunofluorescence staining of skeletal and cardiac muscle injected with LG cells using anti-Ki67 antibodies. Scale bar, 100lm. (E)
Representative immunofluorescence staining of skeletal and cardiac muscle injected with LG cells using anti-cleaved Caspase-3 antibodies. Scale bar, 50lm.
(F–I) Representative whole organ pictures of hearts and skeletal muscle not treated (F) or injected with LG lung adenocarcinoma (G), B16/F10 melanoma
(H), and 4T1 breast cancer cells (I). Tumour area is indicated by a dashed yellow line. Scale bar in F–I, 2 mm. (J–L) Quantification of LG (J), B16 (K), and 4T1
(L) tumour size in skeletal and cardiac muscle at 10 days after cell implantation. In A–C, J–L data are shown as mean ± S.E.M. Statistical significance was deter-
mined using a two-way ANOVA followed by Tukey’s multiple comparison test for data in A, and by Student’s t-test in B, C, J, K, L, *P< 0.05, **P< 0.01, n>_ 4
per group.
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..more active in basal conditions in endothelial cells derived from the skel-
etal muscle compared with those derived from the heart.
Phosphorylation of both Akt and Erk1/2 tended to further increase in
skeletal muscle, but not in cardiac endothelial cells, stimulated with
VEGF in culture, consistent with their different proliferative potential
(Supplementary material online, Figure S7B–F).
We also cultured the same cells in non-adhesive round bottom plates
favouring their organization into spheroids, which were eventually trans-
ferred onto a collagen substrate to allow endothelial cell sprouting.
Primary endothelial cells from skeletal muscle efficiently sprouted and
formed tubular structures extending out of the spheroids over 2 days,
while cardiac endothelial cells essentially remained inside the spheroid
body and minimally migrated out of it (Figure 5E and F). Consistent with
their higher sprouting capacity, muscle-derived spheroids contained a re-
markable number of Apelinþ cells in their sprouts (Figure 5E and G), of-
ten exhibiting the classic tip cell morphology (inset in Figure 5E). In
contrast, cardiac endothelial spheroids contained numerous Apelinþ
cells in their bodies, similar to what was observed in muscle spheroids
(Figure 5E and H), but these cells were not able to sprout (Figure 5E
and G).
Thus, endothelial cells from both muscle types respond to VEGF in-
ducing Apelin expression, but those derived from the heart do not prolif-
erate and are incapable of forming angiogenic sprouts in culture.
3.5 Apelin-positive endothelial cells fail to
form elongated vascular structures in the
heart in response to VEGF
Our data on cultured cells indicate that a comparable number of
Apelinþ cells is induced by VEGF in both skeletal and cardiac muscle, but
they differentially proliferate and form vascular sprouts. We wondered
whether similar differences were also occurring in vivo in the context of
VEGF- and tumour-induced angiogenesis.
First, we focused on the capacity of Apelinþ endothelial cells to form
elongated vascular structures 30 days after AAV-VEGF injection in either
skeletal or cardiac muscle of Apln-CreER; R26mT/mG mice (as schemat-
ically represented in Figure 6A). In control heart and skeletal muscle, the
Figure 5 Cardiac endothelial cells up-regulate Apelin but fail to form vascular structures upon VEGF stimulation in vitro. (A) Representative images of cul-
tured skeletal muscle and cardiac endothelial cells (SMECs and CMECs, respectively) isolated from Apln-CreER; R26mT/mG mice, treated with tamoxifen,
either in the presence or in the absence of VEGF (100 ng/mL) for 48 h. Endothelial cells are labelled with anti-CD31 antibodies. (B) Quantification of EGFPþ
endothelial cells (percentage of CD31þ cells). (C) Representative images of SMECs and CMECs isolated from C57Bl/6 mice either in the presence or in the
absence of VEGF (100 ng/mL) for 48 h. Endothelial cells are labelled with anti-CD31 antibodies and proliferating cells with anti-Ki67 antibodies. (D)
Quantification of Ki67þ endothelial cells (percentage of CD31þ cells). (E) Representative images of SMEC and CMEC spheroids isolated from Apln-CreER;
R26mT/mG mice and let to sprout for 48 h. The boundary between the spheroid body and the sprouts is marked with a dashed white line. The inset shows
an EGFP1 cell, presenting numerous filopodia classically associated to tip cells, at the forefront of a growing sprout. (F and G) Quantification of tdTomatoþ
(F) and EGFPþ (G) area in the sprouts (normalized to the length of the spheroid boundary visible in each field). (H) Quantification of EGFPþ area within
SMEC and CMEC spheroid body (EGFPþ/Hoechstþ area). In B, D, F–H data are shown as mean ± S.E.M. Statistical significance was determined using a two-
way ANOVA followed by Tukey’s multiple comparison test for data in B and D, and by Student’s t-test in F, G, H, **P< 0.01, ***P< 0.001, n>_ 4 per group.
Scale bar in A, C, E 100lm.
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Figure 6 Cardiac endothelial cells up-regulate Apelin but fail to form elongated vascular structures upon VEGF stimulation in vivo. (A) Schematic of AAV
and tamoxifen (Tam) injection in Apln-CreER; R26mT/mG mice for characterization of sorted tdTomatoþ and EGFPþ cells. (B and C) Histograms showing
the number of EGFPþ cells lining in a vascular tube in either skeletal (B) or cardiac (C) muscle injected with AAV-control (left) and AAV-VEGF (right).
Superimposed to each histogram is the density plot (in blue). (D) Representative immunofluorescence staining of skeletal and cardiac muscle of Apln-CreER;
R26mT/mG mice injected with either AAV-control or AAV-VEGF, labelled with anti-ERG antibodies. (E) Representative 3D renderings of 100mm thick sec-
tions from skeletal and cardiac muscle of Apln-CreER; R26mT/mG mice injected with AAV-VEGF. (F–H) Flow cytometry analysis of CD31þ
VEGFR1(VR1)þ cells (F) and DLL4 intensity in either total CD31þ cells (G) or sorted tdTomatoþ and EGFPþ cells (H), purified from cardiac and skeletal
muscle of Apln-CreER; R26mT/mG mice, 7 days after AAV-VEGF injection. Data in F–H are shown as mean ± S.E.M. Statistical significance was determined
using Student’s t-test and one-way ANOVA followed by Tukey’s multiple comparison test for data. *P< 0.05, **P< 0.01, ***P< 0.001. n= 3–6 per group.
Scale bar in D, E 100lm.
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few EGFPþERGþ endothelial cells were all individually spaced. Delivery
of AAV-VEGF to the skeletal muscle resulted in a massive increase in the
number of EGFPþERGþ endothelial cells, which were often incorpo-
rated in elongated vascular structures, reaching up to 15 EGFPþERGþ
endothelial cells positioned in the same tube. In contrast, most of the
EGFPþERGþ endothelial cells in the heart remained as single cells or
formed very short vascular structures, even after VEGF stimulation. The
distribution of the number of EGFPþERGþ endothelial cells in the same
vascular tube is shown for both muscle types in Figure 6B and C, while
representative images are shown in Figure 6D. Only in the skeletal mus-
cle, this distribution was skewed towards the right in response to VEGF,
indicating the generation of long capillaries by EGFPþERGþ endothelial
cells, while no significant changes could be observed in the heart.
Comparable results were obtained in 100lm thick muscle sections, that
better show the three-dimensional organization of the vascular network
(Figure 6E, Supplementary material online, Figure S8A and Movies S1–S4).
In parallel, we also assessed the effect of a 100-fold higher or lower dose
of vector, and again we did not detect any improvement in vessel length
by increasing the dose of VEGF in any of the two muscle types
(Supplementary material online, Figure S3E). The lowest dose of the vec-
tor did not result in any angiogenic response (Supplementary material
online, Figure S3F).
To shed light on the molecular mechanisms underlying the poor elon-
gation of vascular tubes in response to VEGF in the heart, we used flow
cytometry to characterize the expression of VEGFR1 and Dll4, which
are well known to regulate endothelial cell proliferation and the cross-
talk between tip and stalk cells during sprouting angiogenesis.19,26 We
followed the gating strategy shown in Supplementary material online,
Figure S9A–C to separately analyse EGFPþ cells and tdTomatoþEGFP-
cells (possibly representing tip and stalk cells, respectively). We found
that the percentage of VEGFR1þ endothelial cells was significantly de-
creased at Day 7 after AAV-VEGF injection in the skeletal muscle, but
not in the heart (Figure 6F). In parallel, Dll4 was significantly more
expressed in response to VEGF in endothelial cells purified from the
muscle compared with those purified from the heart (Figure 6G). This
up-regulation in the muscle was almost totally sustained by Apelinþ cells,
consistent with their possible tip cell function (Figure 6H). As a result of
increased Notch signalling from tip cells, the Notch-target genes Hes1,
Hey1 and Notch1 itself were more expressed by tdTomatoþEGFP- cells
purified from the skeletal muscle compared with those purified from the
heart (Supplementary material online, Figure S9D–F).
Thus, VEGF stimulates effective angiogenesis and the formation of
elongated vascular structures, relying on Notch signalling, in the skeletal
muscle, but fails to do the same in the heart.
3.6 Apelin-positive endothelial cells fail to
form elongated vascular structures in the
heart in response to cancer cell
implantation
Next, we moved to the cancer model and assessed tumour vessels at
10 days after LG cell implantation (Figure 7A). In the skeletal muscle, ves-
sels included up to nine EGFPþ cells lining in a row in the same vascular
tube inside the tumour area. In contrast, most of the cardiac vessels con-
tained only one or two EGFPþ cells. The results of this quantification are
shown in Figure 7B and representative images in Figure 7C. A comparable
pattern was observed in 100lm thick sections (Figure 7D,
Supplementary material online, Figure S8B and Movies S5 and S6). Similar
to what was observed upon VEGF overexpression, Apelinþ cells were
able to persist and generate elongated vascular structures only in the
context of cancers growing in the skeletal muscle, skewing the distribu-
tion to the right compared with the one observed in the heart
(Figure 7B).
We also analysed the spatial localization of these cells. While EGFPþ
vessels were abundantly present within the central part of the tumour in
the skeletal muscle, most of the EGFPþ cells were concentrated in the
healthy tissue surrounding the tumour mass in the heart. By quantifying
the EGFPþ area in the border region (as defined in methods), we found
that in the heart most of the Apelinþ cells were still present in the
healthy portion of the border 10 days after tumour implantation. In the
skeletal muscle, the same cells had already penetrated inside the neoplas-
tic mass (quantification is shown in Figure 7E and representative images
in Figure 7F). Thus, in the heart sprouting Apelinþ endothelial cells have a
low capability to form elongated vascular structures and penetrate the
tumour mass, consistent with their apoptotic phenotype particularly evi-
dent at Day 6 (Supplementary material online, Figure S5).
Overall, these data support a model in which endothelial cells in both
skeletal and cardiac muscle similarly start expressing Apelin in response
to pro-angiogenic stimuli (i.e. VEGF or molecules secreted by cancer
cells). In the skeletal muscle, Apelinþ cells activate Notch signalling and
drive the formation of new vascular sprouts, which are eventually incor-
porated into arterial vessels. In contrast, Apelinþ cells in the heart persist
for a short period of time, undergo apoptosis and fail to drive an efficient
angiogenic response (Figure 8).
4. Discussion
The results presented in this work provide a definitive evidence that the
adult mammalian heart has a low angiogenic potential. While in the skel-
etal muscle angiogenic stimuli induce Apelin expression in a few endo-
thelial cells, which sprout and lead to the formation of mature new
vessels, in the heart Apelinþ cells are unable to support an efficient
angiogenesis.
The poor angiogenic nature of the adult heart was suggested by our
serendipitous observation that the presence of the same amount of
VEGF in either the skeletal or the cardiac muscle resulted in a very differ-
ent angiogenic response. While VEGF induced a massive increase in the
number of both capillaries and small arteries in the skeletal muscle, in the
heart it resulted in the formation of a modest number of new arteries,
with almost null endothelial cell proliferation.
Thus, we used Apln-CreER; R26mT/mG mice to genetically trace
sprouting endothelial cells and follow their fate upon administration of
pro-angiogenic stimuli. Besides VEGF, which is the most potent and best
characterized angiogenic molecule, we also exploited the capacity of
cancer cells to secrete pro-angiogenic factors. In both cases, i.e. the injec-
tion of either AAV-VEGF or cancer cells, a comparable proportion of
endothelial cells started expressing Apelin in both muscle types. These
cells efficiently formed new capillaries and were incorporated into small
arteries in the skeletal muscle, but not in the heart, in which VEGF-
induced arterioles were essentially Apelin-negative. These data are con-
sistent with those obtained by He et al.,6 who used the same genetic
model to assess the mechanism responsible for the formation of new
vessels during embryonic development and after myocardial infarction.
These investigators found that arteries appearing in the adult heart after
ischaemia did not bear any Apelinþ cells and concluded that new vessels
can be formed in the ischaemic heart only through arteriogenesis,
namely the expansion of pre-existing arterioles, and not true
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angiogenesis.6 Thus, the modest increase in the number of arterioles
that we observed in the heart after AAV-VEGF administration can be
reasonably ascribed to the recruitment and expansion of pre-existing
vessels, in the absence of a true angiogenic response.
When we assessed the basal expression of Apelin in the two muscle
types, we observed that the number of arteries containing Apelinþ
endothelial cells was relatively higher in the untreated skeletal than in the
cardiac muscle. Whether this indicates a spontaneous turnover of endo-
thelial cells within arterial vessels in the skeletal muscle, which, different
from the heart, is an organ endowed with a high regenerative capacity,27
is an interesting hypothesis that requires further validation. Indeed, the
different angiogenic capacity of the heart and the skeletal muscle well
Figure 7 Cardiac endothelial cells up-regulate Apelin but fail to form elongated vascular structures upon cancer cell injection in vivo. (A) Schematic of LG
cells and tamoxifen (Tam) injection in Apln-CreER; R26mT/mG mice. (B) Histograms showing the number of EGFPþ cells lining in a vascular tube in tumours
within either skeletal or cardiac muscle. Superimposed to each histogram is the density plot (in blue). (C) Representative immunofluorescence staining of
skeletal and cardiac muscle of Apln-CreER; R26mT/mG mice injected with LG cells, labelled with anti-CD31 antibodies. (D) Representative 3D renderings
of 100mm thick sections of skeletal and cardiac muscle from Apln-CreER; R26mT/mG mice injected with LG cells. (E) Quantification of the area covered by
EGFPþ cells within each side of the tumour border in both the skeletal and cardiac muscle (P< 0.001). (F) Representative immunofluorescence of tumour
border, defined as the region extending for 200lm in both directions starting from the interface between tumour and healthy tissue, in both the skeletal
and cardiac muscle. Boxed regions are shown as spilt channels in the right panels. Scale bar in C and F, 100lm. n= 6 per group.
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..correlates with the different regenerative potential of the two muscle
types. The regenerative response activated upon any kind of muscle in-
jury entails massive activation of endothelial cells and profound remodel-
ling of the vascular bed.28 Angiogenesis and myogenesis are tightly
coupled and controlled by a set of key molecules, including Periostin,
Oncostatin M, and Apelin itself.28 In contrast, the adult mammalian heart
has a minimal, if not null, regenerative potential29,30 and any damage is
repaired by scarring. Lower vertebrates, such as fish and amphibians, are
able to regenerate the myocardium after damage.31 In these animals, en-
dothelial cells invade the damaged area well before cardiomyocytes start
proliferating, indicating that angiogenesis precedes and is possibly essen-
tial for heart regeneration.32 The neonatal mammalian heart also retains
some regenerative potential for a few days after birth,33 yet the vascular
network observed in the regenerating neonatal heart following apical re-
section is rather incomplete as compared with the normal myocar-
dium,34 again consistent with the poor capacity of the post-natal heart to
form new arteries.
Previous studies claimed the effective formation of new blood vessels
in response to VEGF and other angiogenic molecules in the heart of mul-
tiple species.35 At a deeper analysis, most of these studies either used
transgenic models, in which the angiogenic factor was active already dur-
ing embryonic development, or they did not discriminate between
spouting angiogenesis and other mechanisms of vessel formation. For in-
stance, the cardiac-specific overexpression of another member of the
VEGF family, VEGF-B, resulted in a massive angiogenic response in trans-
genic animals, but did not increase capillary density when delivered to
adult hearts using AAV vectors.36 In addition, many studies delivered the
angiogenic stimulus either using adenoviral vectors or recombinant pro-
teins, both of which have a short half-life in vivo and exert a very transient
effect.37,38 This requires a very early analysis of the angiogenic response,
which likely starts in the heart as in other organs, but fails to progress to
form structured vessels. Indeed, we report that the pro-angiogenic stim-
ulus is sensed by cardiac endothelial cells, as they do activate Apelin ex-
pression, and that the problem occurs at a later stage, during the
vascular elongation phase.
Another difference between the two muscle types, is endothelial cell
density, which appears higher in the heart compared with the skeletal
muscle, when normalized per field. This difference is importantly re-
duced when the number of capillaries is normalized on the number of
nuclei, as nuclei in the cardiac tissue are definitely denser than in the skel-
etal muscle. Thus, we would tend to exclude that the increased vessel
density in the heart results in higher oxygenation and justifies the unre-
sponsiveness of the cardiac muscle to VEGF, as also indicated by the
comparable activation of Apelin expression in the two organs. Indeed,
both muscle types up-regulated Apelin early after the injection of either
VEGF or cancer cells, indicating that they are equally able to sense pro-
angiogenic stimuli at the individual cell level. Increasing the dose of VEGF,
by injecting a 100-fold more concentrated AAV vector, did not rescue
the responsiveness of cardiac endothelial cells to angiogenic stimulation,
nor increased the angiogenic response in the skeletal muscle, consistent
with recent evidence that excessive VEGF stimulation does not result in
functional angiogenesis.39
Apelin up-regulation was also observed in response to VEGF in pri-
mary endothelial cells, purified from both skeletal and cardiac muscle,
Figure 8 Model showing the differential response of endothelial cells from the cardiac and skeletal muscle to pro-angiogenic stimuli. In response to a pro-
angiogenic stimulus, such as VEGF or additional molecules secreted by cancer cells, a few endothelial cells in the skeletal muscle start expressing Apelin.
These Apelinþ cells efficiently sprout, activate Dll4/Notch1 signalling and drive the formation of new vessels, to be eventually incorporated into arteries. In
the heart, the same stimulus leads to a similar activation of Apelin in endothelial cells, which, however, only transiently persist and fail to form elongated vas-
cular structures.
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and grown ex vivo as either a monolayer or spheroids. While skeletal
muscle-derived endothelial cells increased their proliferation and sprout-
ing upon VEGF stimulation, cardiac endothelial cells did not increase
their growth rate and failed to sprout from the spheroid body. Despite
comparable levels of VEGFR2, downstream signalling was more active in
cells purified from the skeletal muscle compared with those purified
from the heart, both in basal conditions and upon VEGF stimulation.
These data suggest that endothelial cells in both muscle types can spe-
cialize into tip cells, characterized by high levels of Apelin expression,
and that a failure in the subsequent induction of stalk cell proliferation
specifically occurs in cardiac endothelial cells. Consistently, in the skeletal
muscle, the angiogenic process effectively proceeded and Apelinþ endo-
thelial cells, along with their progeny, were incorporated into elongated
vascular structures. In contrast, in the heart most of the Apelinþ endo-
thelial cells stayed as single cells and died by apoptosis. When we fol-
lowed their fate over time in the tumour model, we observed that these
cells were mostly retained within the tumour border and failed to pene-
trate the neoplastic mass.
Can this poor angiogenic response be associated to the low incidence
of cancer and metastasis in the heart? Primary and secondary cardiac
tumours are indeed extremely uncommon,40 despite the fact that the
heart is among the most vascularized organs. Our results show that the
experiential injection of cancer cells in the heart invariably resulted in
poor cancer growth and inefficient angiogenesis.
Understanding the mechanisms blocking angiogenesis in the heart
could thus offer novel opportunities for both interfering with cancer
growth and promoting cardiac revascularization. We provide evidence
that VEGFR1 and Dll4/Notch1 signalling are differentially regulated in en-
dothelial cells purified from either the skeletal or the cardiac muscle, pre-
viously stimulated with VEGF. This could reflect a defective tip-to-stalk
cell communication specifically occurring in the heart. Alternatively, the
mechanism behind vessel elongation could be organ-specific and the tra-
ditional model of Notch1-dependent tip-to-stalk cell signalling, described
in the retina, may not be necessarily applicable to other tissues. Our find-
ings provide the base and experimental models for future investigation,
aimed at clarifying the organotypic features of cardiac angiogenesis and
their possible therapeutic exploitation.
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Translational perspective
Cardiac ischaemia is a leading cause of morbidity and mortality worldwide. Various clinical trials have attempted to revascularize ischaemic hearts
through the delivery of pro-angiogenic molecules, but they have invariably failed. Our results indicate that cardiac endothelial cells sense pro-angio-
genic stimuli but are not able to drive an efficient angiogenic response. This poor angiogenic potential is also associated with reduced growth of can-
cer cells in the heart. This work provides some mechanisms behind the poor angiogenic capacity of the heart and paves the way to future strategies
for the therapy of both cancer and cardiac ischaemia.
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